Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Nektar Therapeutics (NASDAQ:NKTR) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $4.08.

NKTR has been the subject of several recent analyst reports. B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price objective for the company. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a report on Monday, January 13th.

Insider Activity

In other Nektar Therapeutics news, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total value of $47,464.95. Following the completion of the sale, the chief executive officer now owns 1,195,710 shares in the company, valued at approximately $1,207,667.10. This trade represents a 3.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total value of $48,048.10. Following the completion of the transaction, the insider now owns 326,904 shares in the company, valued at $307,289.76. The trade was a 13.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 155,575 shares of company stock worth $149,878 over the last quarter. Insiders own 3.71% of the company’s stock.

Institutional Investors Weigh In On Nektar Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Valence8 US LP purchased a new position in Nektar Therapeutics in the third quarter valued at about $34,000. Intech Investment Management LLC purchased a new position in Nektar Therapeutics in the third quarter valued at approximately $41,000. XTX Topco Ltd bought a new position in Nektar Therapeutics during the third quarter valued at $46,000. Erste Asset Management GmbH purchased a new stake in Nektar Therapeutics in the third quarter worth $61,000. Finally, Moloney Securities Asset Management LLC raised its stake in shares of Nektar Therapeutics by 42.4% in the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 14,895 shares during the period. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Stock Down 3.6 %

Shares of Nektar Therapeutics stock opened at $0.68 on Friday. The stock has a market cap of $124.69 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. The company’s fifty day moving average is $0.95 and its 200 day moving average is $1.15. Nektar Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. The business had revenue of $24.12 million for the quarter, compared to analyst estimates of $15.54 million. During the same quarter in the previous year, the business earned ($0.19) earnings per share. As a group, equities analysts anticipate that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.